The systemic effects of @entity6839 eye drops were investigated in 35 @entity1 divided into three groups: 1. (15 asthmatics); 2. (10 non-asthmatic @entity1 suffering from @entity726 ); 3. (10 elderly control subjects). A placebo eye drops was given at time 0, the @entity6839 maleate drops were given at time 30 mn. The control parameters were checked every 15 minutes. They did not show variations under placebo. After administration of @entity6839 , @entity551 as well as vital capacity remained unchanged. Heart rate decreased in 91% of subjects by a mean: 18.5% and, extreme 38%: @entity1168 was always sino-atrial and there was a dose effect relationship. Also F.E.V., decreased in 13 of the 15 asthmatics and in 2 @entity1 with chronic @entity3617 : in 4 @entity1 the decrease in flow exceeded 20%. The importance of @entity6839 in the treatment of open-angle chronic @entity726 is well-established, but the results reported here and else where emphazing frequent risks should induce prescribers to comply with the rules of good use: analysis of previous history, and compliance with general contra-indications to beta blockers. Routine E.C.G. and strict adjustment of dosage is recommended.

[Evaluation of the systemic effects of XXXX in eye drops].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity3617 :: ('MESH:D001991', 'Disease') :: ['bronchitis'] @entity6839 :: ('MESH:D013999', 'Chemical') :: ['timolol'] @entity726 :: ('MESH:D005901', 'Disease') :: ['glaucoma'] @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic and diastolic blood pressures'] @entity1168 :: ('MESH:D001919', 'Disease') :: ['Bradycardia']
@entity6839 :: (MESH:D013999,Chemical) :: ['timolol maleate']
